Knopp Neurosciences announces: Data from Phase 2 Study of dexpramipexole in ALS published in Nature Medicine November 21, 2011
Reaction Biology Corporation Unveils Largest Kinase Profiling Data Set in Nature Biotechnology Publication October 31, 2011
Reaction Biology Now Offers Recombinant Methyltransferases to Complement Its Existing Epigenetic Services October, 24, 2011
Celsense, Inc. Launches a New Dual-mode Imaging Agent Enabling Inflammation Detection by MRI and Fluorescence August 20, 2011
Celsense, Inc. Announces First Clinical Trial Authorization by the US Food and Drug Administration (FDA) for Use of Its Cell Tracking Imaging Product Cell Sense June 27, 2011
The First IND Submitted to the US Food and Drug Administration Using Cell Sense in a Clinical Trial May 10, 2011
ALS Association of Western Pennsylvania to Honor Knopp Biosciences with Anne Lewis Humanitarian Award March 31, 2011
Knopp Biosciences Announces Hiring of Suresh Khemani as VP of Commercial and Clinical Affairs 11/30/2010
Reaction Biology
Receives NCI Grant Award for Epigenetic Platform August 11, 2010
Knopp Neurosciences Presents Further Encouraging Trends in its Phase 2 Study of KNS-760704 (Dexpramipexole) in ALS April 16, 2010
Novel Imaging Software Released by Celsense, Inc. March 18, 2010
Celsense, Inc. Launches a Dual–Mode Imaging Reagent Enabling Cell Detection by MRI and Fluorescence January 19, 2010
New Journal Article Offers In-Depth Analysis of Biological Impact of Celsense’s Cell Labeling Product on Human Dendritic Cells January 10, 2010
Knopp Neurosciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS December 9, 2009
Knopp Neurosciences Receives FDA Fast Track Designation for KNS-760704 in ALS September 2, 2009
Knopp Neurosciences to Present Phase 2 Results of KNS-760704 in ALS August 11, 2009
Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use June 2, 2009
Philips and Immunetrics Join Forces to Research Advanced Solutions for Infectious Disease in Critical Care February 3, 2009
Knopp Neurosciences Completes Series B2 Financing, Raising Total Capitalization to $27 Million November 19, 2008
City Making Advances in Biosciences as Local Companies' Reputations Grow June 1, 2008
Celsense, Inc. Announces Strategic Alliance with m2m Imaging May 2, 2008
Knopp Neurosciences Initiates Phase 2 Study of KNS-760704 in Amyotrophic Lateral Sclerosis April 8, 2008
KNS-760704 in ALS Featured in BioCentury April 3, 2008
Celsense, Inc. Announces Sale of Series B Shares March 22, 2008
Celsense, Inc. Announces Exhibit at 2008 ISMRM Conference March 22, 2008
Celsense, Inc. Announces SBIR Award Feburary 15, 2008
Knopp Neurosciences Completes First Series B Financing of $10 Million January 22, 2008
Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-760704 December 3, 2007
Knopp Neurosciences Receives Orphan Designation October 15, 2007
Celsense, Inc. Announces New Product October 4, 2007
Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy October 3, 2007
Knopp Sponsors Albert Schweitzer Haiti Benefit September 28, 2007
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 September 24, 2007
Celsense, Inc. Announces First Product Sales July 22, 2007
Celsense, Inc. Completes Second Series A Financing July 16, 2007
